Belantamab mafodotin induces immunogenic cell death within 24 h post‐administration in newly diagnosed multiple myeloma patients. Issue 3 (30th December 2022) - Kostopoulos, Ioannis V.; Kakalis, Antonis; Birmpilis, Anastasios; Angelis, Nikolaos; Orologas‐Stavrou, Nikolaos; Rousakis, Pantelis; Panteli, Chrysanthi; Gavriatopoulou, Maria; Kastritis, Efstathios; Dimopoulos, Meletios‐Athanasios; Tsitsilonis, Ourania; Terpos, Evangelos